Related Experiment Videos
Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement
B E Loveland1, R W Johnstone, S M Russell
1Austin Research Institute, Heidelberg, Victoria, Australia.
Transplant Immunology
|January 1, 1993
Summary
To prevent hyperacute graft rejection in xenotransplantation, researchers explored using CD46 (membrane cofactor protein) to regulate complement activation. This study tested CD46 isoforms in vitro to assess their potential in reducing rejection responses.
Area of Science:
- Transplantation immunology
- Molecular biology
- Biochemistry
Background:
- Organ transplantation demand exceeds donor availability, making xenotransplantation a critical area of research.
- Hyperacute graft rejection, driven by xenoreactive antibodies and complement activation, is a major barrier to xenotransplantation success.
- Modulating the complement cascade with regulatory molecules is proposed to mitigate hyperacute rejection.
Purpose of the Study:
- To investigate the potential of CD46 (membrane cofactor protein) isoforms in preventing hyperacute xenograft rejection.
- To establish an in vitro model for assessing complement regulatory functions of CD46.
- To compare the functional differences between CD46 isoforms when expressed in cultured cells.
Main Methods:
- Transfection of Chinese Hamster Ovary (CHO-K1) cells with cDNA encoding different CD46 isoforms.
- Selection and identification of transfected cells using methionine sulphoximine and monoclonal antibodies.
- Assay of CD46 function using a complement-dependent cell lysis assay with normal human serum.
Main Results:
- Normal human serum containing xenoreactive antibodies induced lysis of CHO cells, demonstrating an in vitro model of hyperacute rejection.
- CD46 expression was successfully established in CHO-K1 cells.
- The study laid the groundwork for assessing CD46's efficacy in reducing complement-mediated rejection.
Conclusions:
- CD46 (membrane cofactor protein) shows promise as a therapeutic target to inhibit complement activation in xenotransplantation.
- Further research into specific CD46 isoforms is warranted to optimize strategies for preventing hyperacute rejection.
- This in vitro approach provides a foundation for developing genetically modified donor animals to improve xenograft survival.